Review

Neurosurgical Clinical Trials for Glioblastoma: Current and Future Directions

Ashish H. Shah 1,2 and John D. Heiss 1,*

1 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA; ashah@med.miami.edu
2 Department of Neurosurgery, University of Miami School of Medicine, Miami, FL 33136, USA
* Correspondence: heiss@ninds.nih.gov

Abstract: The mainstays of glioblastoma treatment, maximal safe resection, radiotherapy preserving neurological function, and temozolomide (TMZ) chemotherapy have not changed for the past 17 years despite significant advances in the understanding of the genetics and molecular biology of glioblastoma. This review highlights the neurosurgical foundation for glioblastoma therapy. Here, we review the neurosurgeon’s role in several new and clinically-approved treatments for glioblastoma. We describe delivery techniques such as blood–brain barrier disruption and convection-enhanced delivery (CED) that may be used to deliver therapeutic agents to tumor tissue in higher concentrations than oral or intravenous delivery. We mention pivotal clinical trials of immunotherapy for glioblastoma and explain their outcomes. Finally, we take a glimpse at ongoing clinical trials and promising translational studies to predict ways that new therapies may improve the prognosis of patients with glioblastoma.

Keywords: glioblastoma; brain mapping; temozolomide; radiotherapy; connection-enhanced delivery; immunotherapy; tissue-treating fields; blood–brain barrier opening

1. Introduction

Standard neurosurgery for cerebral glioma requires maximal safe tumor resection. For low-grade tumors (WHO Grade II–III), maximal safe resection of the tumor confers an improved outcome without compromising functional outcomes [1,2]. In the case of glioblastoma, the location of the bulk of the tumor relative to eloquent brain areas dictates the safest and most effective surgical approach. Here, we define eloquent cortex as areas with readily evident neurological function that if damaged results in “disabling neurological deficit” such as corticospinal tracts or dominant receptive/language areas [3]. Jelsma and Bucy reported in 1969 that with glioblastoma (WHO Grade IV glioma), extensive surgery and postoperative radiation extended survival time to 7.5 months compared to 2.5 months with limited resection and postoperative radiation [4]. Survival was 10.5 months in non-central tumors in eloquent brain areas and 4 months with central tumors, those involving the precentral gyrus, Broca’s area, or the Sylvian fissure of the dominant hemisphere. Before surgery, the proportion of patients in excellent or good condition was 31% with non-central and 26% with central tumors. At 3 months after surgery, 78% of patients in the patient group with non-central tumors were in excellent or good condition compared to only 42% of patients with central tumors. Extensive surgery improved function by removing tumors’ mass effect and reducing elevated intracranial pressure.

The role of radiotherapy in glioblastoma therapy was confirmed in 1979 by Walker, Strike, and Sheline. At that time, survival time was 18 weeks without radiation, 28 weeks with 50 Gy, 36 weeks with 55 Gy, and 42 weeks with 60 Gy [5]. Almost three decades later, Stupp et al. verified the survival benefit of more extensive tumor resection results in 2005 in their study of 573 patients with glioblastoma who were randomized to receive radiotherapy (60 Gy) versus radiotherapy (60 Gy) plus temozolomide. Median survival
in the temozolomide and radiotherapy arm was 15.8 months in the resection group and 9.4 months in the biopsy-only group. In patients who received radiotherapy (RT) alone, surgical resection (S) improved survival by 12.9 months (S + RT) vs. 7.9 months in the RT alone group [6].

Nevertheless, whole-brain radiotherapy has a greater chance of precipitating cognitive dysfunction from bihemispheric injury than focal brain irradiation. Since tumor recurrences occur most often within 2 cm of the postoperative resection cavity, partial brain irradiation to the volume of 60 Gy in 30 fractions is recommended in patients less than 70, and 40 Gy in 15 fractions for patients over 70 years of age with good performance status [7]. Glioblastoma treatment with maximal safe surgical resection followed by concurrent radiotherapy and temozolomide (TMZ) chemotherapy has been standard for glioblastoma since the 2005 Stupp study. Although this study demonstrated that surgery, radiotherapy, and chemotherapy extended survival in glioblastoma, their effects are limited, and the median life expectancy was 14.6 months [6]. The rest of this review describes the subsequent efforts to improve neurosurgical treatment of glioblastoma further.

2. Development and Refinement of Glioblastoma Treatments

2.1. Efforts to Improve the Completeness of Tumor Resection

2.1.1. Cortical and Subcortical Electrical Stimulation Mapping

Over the past decade, a consensus agreement was reached among authors in the neurosurgical literature that more extensive tumor resection improves glioblastoma life expectancy. Two separate studies from the UCSF and MD Anderson Cancer Center reported that MRI-visible glioblastoma resection needed to reach a threshold of at least 78%, preferably greater (98 to 100%), to provide a relevant survival benefit (Table 1) [8,9]. (There is abundant evidence supporting maximal safe resection in non-eloquent brain regions. Neurosurgeons have recently advocated for the supramaximal resection of a glioma when feasible to improve overall survival further. Several groups advocate resecting a substantial margin beyond the contrast-enhancing rim for non-eloquent-location high-grade gliomas (~1–2 cm). In a series of reports on this subject, supramaximal resection resulted in patient survival of 20.9–30.7 months [10–12]. However, supramaximal resection is impossible in all patients because a bulk tumor invades into the adjacent eloquent cortical and subcortical structures. The survival advantage of the complete resection of MRI-visible tumors in glioblastoma was reported to be 2.9 months in one study and 6.4 months in another [6,8]. The survival advantage of complete tumor resection is much longer in lower-grade gliomas than in glioblastoma (Table 1).

Table 1. Prognostic impact of extent of resection.

| Brain Tumor Type and WHO Grade | Invasive | Complete Resection Possible | Life Expectancy (Months) Biopsy | Life Expectancy (Months) MR Incomplete Resection | Life Expectancy (Months) MR Complete Resection | Survival Advantage (Months) with MR Complete Resection Compared to Incomplete Resection |
|-------------------------------|---------|----------------------------|-------------------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------|
| Neuronal DNET Ganglioglioma    | No      | Yes; if outside eloquent structures | Prolonged                    | Prolonged                                    | Prolonged                                    | Uncertain: residual tumors require additional surgery                             |
| Pilocytic astrocytoma  II     |          |                               |                               |                                               |                                               |                                                                                  |
| Low-grade astrocytoma and oligodendroglioma III | Yes    | No                            | 61                            | 90.5                                         |                                               | 29.5                                                                             |
| Anaplastic astrocytoma and oligodendroglioma IV | Yes    | No                            | 64.9                          | 75.2                                         |                                               | 10.3                                                                             |
| Glioblastoma multiforme       | Yes     | No                            | 9.4†                          | 14.2                                         | 15.8†                                        | 6.4†                                                                             |

† [6].

The goal of maximal tumor cytoreduction from the non-eloquent brain depends on accurate knowledge of the relationship between the margin of the eloquent brain and the margin of the tumor. To maximize tumor removal from the non-eloquent brain,
the neurosurgeon utilizes techniques to delineate the margin between the tumor and eloquent cerebral cortex and subcortical white matter tracts. Intraoperative electrical stimulation mapping techniques, perfected to identify the eloquent cortex during awake epilepsy surgery procedures, were applied to patients with brain tumors [13]. Electrical stimulation positively affects the motor cortex, evoking movement, and the somatosensory cortex, producing localized paresthesias. Electrical stimulation has negative effects on the completion of language and memory tasks. The margin width between a language site and the resection margin was found to determine the risk of a temporary or permanent language deficit after the resection. No deficits occurred with 20 mm or broader margins, temporary deficits with margins between 20 and 7 mm, and permanent deficits with 7 mm or less [13]. Sanai and colleagues used language mapping during glioma resection and a margin of 1 cm from language areas. Only 1.6% of glioma patients had a persistent language deficit at 6 months after awake tumor resection [8]. The avoidance of brain injury outside the resection cavity depends on the preservation of the arteries of passage and prominent cortical veins (veins of Labbé and Trolard) and recognition of adjacent cortical/subcortical tracts. Modern anesthetic techniques allow patients to be awake for electrical mapping and tumor resection but unaware of the rest of the surgical procedure. Sedation or general anesthesia during the craniotomy’s opening and closing improves patient comfort and cooperativeness and promotes the maximal extent of resection and minimal morbidity [8,14,15]. Some neurosurgeons prefer their patients to stay awake throughout the procedure and provide short-acting opioids like remifentanil for pain uncontrolled by local anesthesia [16]. Electrical stimulation mapping establishes a border that would result in neurological deficit if crossed. Glioblastoma cells always infiltrate throughout the brain and into eloquent brain regions, and sound judgment prevents straying into eloquent brain regions beyond the safe limit of neurosurgical resection [17].

2.1.2. Assessment of the Extent of Tumor Resection in the Intraoperative MRI Suite

Another surgical adjunct to enhance the extent of tumor resection is intraoperative MRI. A randomized trial of patients with a high-grade glioma confirmed that patients with a complete tumor resection had a longer PFS than patients with a residual tumor (median 226 [162–290] vs. 98 days [92–104], \( p = 0.003 \)). This finding highlights the prognostic significance of complete tumor resection. Although a significantly higher proportion of patients in the intraoperative MRI group had a gross total resection (96% vs. 68%, \( p = 0.023 \)), progression-free survival showed only a trend toward significance (\( p = 0.083 \)). In this study, the patients most likely to benefit from intraoperative MRI were the 28% of patients in the iMRI group who would not have received a gross total resection in the microsurgery group. The other 68% percent of patients in either group had a gross total resection or would not be expected to have different outcomes in terms of progression-free survival [18]. Cortical mapping can also be performed in the intraoperative MRI suite for tumors near eloquent regions. After initial tumor resection, MRI scans are performed, and if residual is detected in a surgically accessible area, more tumor is subsequently removed. Therefore, at most, two intraoperative MRI scanning sessions, one after the initial resection and one after the subsequent resection of the residual MRI-visible tumor, are required to confirm tumor resection from non-eloquent regions [19]. Over the last decade, iMRI has become a mainstay of surgical neuro-oncology and has directly impacted onco-functional outcomes for glioma patients [20].

Comparison of Craniotomy for Glioblastoma in the Intraoperative MRI (iMRI) Suite versus Neuronavigation in a Conventional Operating Room

1. Advantage of iMRI suite vs. Standard Neurosurgical operating room (OR)
   - Intraoperative evaluation of completeness of resection of tumors is possible in the iMRI suite but not in the conventional OR
     - Allows recognition and removal of residual tumor during the same procedure
     - More substantial resections may improve the prognosis
2. Disadvantages of iMRI suite vs. Standard Neurosurgical OR
   - The duration of surgery is increased by intraoperative MRI scan time and transitions from the operating position to the MRI scanner bore
     • neuronavigation based on preoperative MRI and frameless stereotaxy can reduce this time by providing guidance for centering incisions and locating the tumor, eliminating initial iMRI scans immediately before surgery
     • reducing iMRI scan to immediately after resection with and without contrast also saves time and allows iMRI’s quality control function of detecting residual tumor
   - Head holders are less adjustable; positioning is less flexible
   - The operating table in the iMRI suite is firmer than the standard OR table
   - Special safety considerations are required
     • MR compatible instruments
     • Must avoid the receiving coil contacting the body and looping wires

2.1.3. Use of Fluorescent Labeling and Resection of Fluorescent Labeled Tumor Tissue

Another surgical adjunct to increase the volume of malignant glioma resection is oral 5-aminolevulinic acid (5-ALA). 5-ALA penetrates the blood–brain barrier of the MRI-enhancing tumor volume and highlights the extent of the tumor intraoperatively. 5-ALA is a natural precursor molecule in heme synthesis that is selectively converted to fluorescent porphyrins in malignant or highly metabolic tissue. In a randomized controlled multicenter phase III trial by Stummer and colleagues, the rate of gross total resection was 65% in the 5-ALA group compared to 36% in the white-light microscopy alone group [21]. The gross total resection rate of 65% was slightly less than in the microsurgery control group in the intraoperative MRI study of Senft et al. in 2011 [18]. After surgery, temporary neurologic deficits occurred more frequently after 5-ALA use, consistent with more extensive resections, but, longer term, the 5-ALA group had improved progression-free survival at six months (PFS6), better function, and less need for repeat surgical resection [22]. Stummer’s and other studies of 5-ALA led the FDA to approve the drug as an intraoperative optical imaging agent in patients with suspected high-grade glioma in 2017 [23].

* Randomized clinical trial.

Using 5-Aminolevulinic acid (5-ALA) to Highlight Glioblastoma

1. 5-ALA is an adjunct measure for identifying high-grade glioma tissue during a craniotomy
   a. 5-ALA is taken up by GBM cells and metabolized to protoporphyrin, which accumulates in tumor tissue Peak uptake 6 hours after preoperative oral administration
   b. Glioma visualized using a filter on the operating microscope Violet light visualizes protoporphyrin IX
   c. Does not identify low-grade glioma
   d. The brain surrounding the tumor does not enhance with 5-ALA.

2. Improves removal of the tumor from the non-eloquent brain
   a. Phase III clinical trial of malignant glioma—322 patients *
      
      Gross total resection: 
      Microsurgery: 36% 5-ALA guided: 65%
      6 m PFS: 21% 41%
   b. 5-ALA does not affect neurological function
   c. Preserves survival quality
      No difference in serious adverse events and adverse events between the microsurgery and 5-ALA groups

In some centers, other known fluorescent labeling technologies have been proposed such as sodium fluorescein and indocyanine green. Although indocyanine green and fluorescein have lower specificity for gliomas than 5-ALA, both fluorophores may be useful intraoperatively. Sodium fluorescein accumulates in areas of blood–brain barrier disruption,
particularly in the contrast-enhancing tumor wall of high-grade gliomas. Fluorescein-guided glioma surgery has been well-described and has been associated with an improved PFS in small retrospective studies [24]. However, because sodium fluorescein is found in the tumor extracellular space, non-specific labelling has been reported after surgical manipulation. The overall sensitivity and specificity of fluorescein for gliomas remains approximately 85% and 90%, respectively [25]. Similarly, indocyanine green has been proposed as an alternative for fluorescent-guided glioma surgery. Although primarily used in cerebrovascular surgery, indocyanine green accumulates within a few minutes after administration due to peritumoral vascular permeability [26]. However, its low half-life, rapid excretion, and non-specific uptake limit its overall applicability to glioma surgery.

2.1.4. Improving Extent of Resection of Gliomas Using Intraoperative Raman Histology

Over the last five years, Raman Histology has been proposed as an important surgical adjunct to improve the extent of the resection of gliomas by identifying tumor infiltration in situ. Raman Histology is capable of rapidly generating histological images of specimens in a label-free manner by detecting molecular vibrations of scattered light. Using this stimulated Raman scattering approach, multicolor images are generated that are comparable to conventional Hematoxylin and Eosin staining [27,28]. As such, serial tumor sampling around the tumor margin is feasible and can permit rapid intraoperative tumor diagnoses [29–31]. Similar techniques are also being developed using a hand-held device capable of delineating glioma Raman spectra intraoperatively [32,33]. Overall, these techniques may facilitate the detection of glioma infiltration and, ultimately, improve outcomes for patients by improving the extent of resection.

2.2. Efforts to Prevent Neurological Deficits Resulting from Tumor Resection

Protecting quality of life and onco-functional status is critical for patients with malignant gliomas [34–36]. The decision to opt for aggressive surgical resection must be counterbalanced by the risks of diminishing the patient’s neuropsychological and functional status. McGirt and colleagues highlighted the effect of a surgically-induced neurologic deficit on survival after surgical treatment of glioblastoma. They retrospectively reviewed 306 consecutive patients, 18 to 70 years of age, with newly diagnosed glioblastoma and good performance documented by Karnofsky performance scores (80–100). Although the 89% of patients who were deficit free after surgery had a 12.8-month median survival, the 5% of patients with a new language deficit had a 9.6-month median survival, and the 6% of patients with a new motor deficit had a 9.0-month median survival. After glioblastoma surgery, a permanent neurological deficit shortened survival by 3 to 4 months and reduced quality of life [37].

Mapping techniques identify eloquent cortex and subcortical tracts involved in expressive and receptive language, motor function, and tactile sensation that are avoided to prevent a neurological deficit. Resections with less than a 1 cm margin from these eloquent cortical areas risk temporary or permanent neurological deficits, with temporary deficits from procedural edema and permanent deficits due to microvascular disruption and resection margin infarcts. Recent research shows that some patients with preserved language, motor, and somatosensory function experience disabling cognitive losses after surgical resections. Cognitive deficits arise from the disruption of cortical networks involved in executive function, attention, default state non-goal oriented tasks, limbic function, salience, and sensorimotor and visual function [38]. The recent integration of MR-based connectomics and diffuse tensor imaging has facilitated the detection of vital subcortical tracts and can help with operative planning [39–41]. Operative approaches may be tailored to avoid some of these networks, and judgment is required to assess if the cognitive deficit risk justifies tumor resection interrupting one or more networks.
2.3. Less Invasive Glioblastoma Surgical Treatments

Laser Interstitial Thermal Therapy

For some deep-seated inoperable glioblastomas, tailored surgical approaches to minimize adjacent white matter disruption while maximizing cytoreduction should be considered. Over the past several years, laser interstitial thermal therapy (LITT) has been popularized for gliomas. Using stereotactic navigation through a 3 mm incision, a laser catheter can be inserted into a target lesion, which can then be coagulated with real-time MR thermography. Although restricted to smaller lesions (<2.4 cm), LITT is particularly suited for treating deep, surgically inaccessible tumors [42,43]. Initial experiences using LITT for gliomas suggest that adequate cytoreduction (>70%) can improve overall survival. Overall survival in newly diagnosed glioblastomas was reported as between 14–24 months in some series. Survival increased more in patients with smaller lesions and there was a greater extent of ablation [44–46]. For patients with deep lesions who would otherwise receive a biopsy without tumor resection, LITT can provide cytoreduction that facilitates subsequent chemoradiation. Clinical studies also suggest that LITT may incite or potentiate a local immune response and transiently open the blood–brain barrier to systemic immune cells [44,47,48]. Since the LITT incision is tiny and blood flaps are unnecessary, chemoradia
tion can be started within 7–10 days of LITT, allowing patients receiving LITT to be treated sooner after the cytoreduction procedure than patients undergoing conventional resections through much larger surgical openings.

2.4. Non-Surgical Glioblastoma Treatments

2.4.1. Tumor-Treating Electric Fields

Tumor-treating electric fields disrupt cancer cell division. A randomized trial in GBM patients previously treated with chemoradiotherapy showed that patients treated with the tumor-treating fields (TTFs) and temozolomide (TMZ) had a median progression-free survival of 7.1 months compared to 4.0 months with TMZ alone (p = 0.001). Median survival was 20.5 months in the TMZ plus tumor-treating fields and 15.6 months in the TMZ alone group (p = 0.004). There was a 43% incidence of mild to moderate skin reactions and a 2% incidence of severe skin reactions (medical device site reactions beneath the transducer arrays) in patients treated with tumor-treating fields plus temozolomide [49]. Seizures and headaches were more frequent in the group treated with tumor-treating fields. In 2011, the FDA approved, under the Premarket Authorization (PMA), a pathway treatment of recurrent or progressive glioblastoma (GBM) using a TTF delivery system. In 2015, the FDA expanded the device’s approval to include the treatment of newly diagnosed GBM when combined with TMZ. This new treatment extends the survival of GBM patients for several months, although skin reactions, prolonged machine use, and other side effects can deter its use.

2.4.2. Immunotherapy and Virotherapy

Immunotherapy using immune checkpoint inhibitors is FDA-approved for treating metastatic melanoma and other cancers. Thus far, clinical trials of immune checkpoint inhibitors in patients with GBM have been unsuccessful. However, there is enthusiasm about developing immunotherapy for GBM because of the limited effectiveness of the current standard therapy of surgical resection of the primary tumor mass and chemoradiation of the residual tumor. Immunotherapy depends on the established capacity of activated lymphocytes to freely enter and exit the central nervous system (CNS) through the blood–brain barrier. Immune checkpoint inhibitors suppress the immune activation of tumors. Checkpoint inhibitors include cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1). Ipilimumab, a monoclonal antibody against CTLA-4, received FDA approval in 2011 to treat metastatic melanoma. Nivolumab and pembrolizumab are monoclonal antibodies inhibiting the PD1 receptor that received FDA approval in 2014, and also for the treatment of malignant melanoma. The Phase III trial of nivolumab versus bevacizumab (anti-vascular endothelial growth factor A (anti-VEGF-A) humanized
monoclonal antibody) in 369 randomized patients with glioblastoma at first recurrence following standard radiation and temozolomide therapy demonstrated a higher objective response with bevacizumab (23.1%) than with nivolumab (7.8%). The 12-month overall survival (OS) was 42% in both groups [50]. A single immune checkpoint inhibitor such as nivolumab was ineffective. Additional clinical trials using Chimeric Antigen Receptor-T-Cells (CAR-T) have been proposed for glioblastoma. Phase 1 clinical trials targeting the EGFR-VIII mutation have been conducted with modest results (median overall survival 6.9–8 months) [51,52]. Other clinical trials focusing on several epitopes such as GD2, CD147, and B7-H3 are currently being conducted [53]. However, CAR-T cell therapy is restricted by several important factors including the limited penetration of solid tumors, immuno-suppressive tumor microenvironment, and heterogenous expression of tumor antigens. Future immunotherapy trials for glioblastoma must employ strategies that enable stronger immune reactions to tumor cells. Immunotherapy may be enhanced by other treatments such as LITT and tumor-treating fields and be more effective as a treatment adjuvant than as a sole treatment. Combination immunotherapeutics that utilize antisense oligonucleotides have also been proposed to target IGF type 1 receptors. The recent IGV-001 trial treated autologous tumor cells with antisense oligonucleotides against IGF-001 ex vivo, irradiated the tumor cells, and reimplanted the cells intraperitoneally using biodiffusion chambers. In the highest dose cohort, overall survival and PFS were 38.2 months and 17.1 months, respectively, for newly diagnosed gliomas [54].

Other efforts to improve outcomes for glioblastoma have relied on viral-based gene therapy and oncolytic virotherapy. Initial studies focusing on viral-based gene therapy have relied on replication-defective adenoviral vectors, which did not demonstrate significant tumor transduction beyond the injection site [35]. However, with the advent of replication-competent viruses, virotherapy may adapt to the evolving tumor microenvironment. Newer generation viral-based gene therapies used replication-competent retroviruses (Maloney murine leukemia virus) and herpes simplex virus to transduce host cancer cells [56,57]. Prodrug activating viral-based gene therapy facilitates tumor selective viral transduction and introduces a “suicide” transgene that converts a non-toxic prodrug into a intracellular chemotherapeutic. The recent Toca511 Phase III clinical trial evaluated the efficacy of a retroviral-mediated gene therapy for recurrent glioblastoma and did not reach its study endpoints [58]. However, there was a significant survival benefit in IDH-mutant and anaplastic astrocytoma. Therefore, selecting the proper patient/subgroup for gene therapy trials remains essential.

Novel oncolytic virotherapies that exploit immunotherapy have recently been described, suggesting that certain virotherapies can induce the adaptative and innate immune response. Of these, oncolytic herpes simplex viruses such as RQNestin have demonstrated increased natural killer cells and tumor-infiltrating macrophages and lymphocytes shortly after viral injection [59–61]. Other viral vectors utilizing replication-competent adenoviral vectors (Delta24-RGD) are also being investigated in recurrent gliomas. A recent Phase I clinical trial in current gliomas demonstrated that nearly 20% of patients had tumor responses after treatment with Delta24-RGD with increased peritumoral cytokine levels and tumor-infiltrating lymphocytes [62]. Additionally, other oncolytic virotherapies such as Delta-24-ACT that co-express immunostimulatory ligands are also being investigated in preclinical models to stimulate a robust antitumor immune response [63].

2.4.3. Methods to Improve the Delivery of Therapeutic Agents to Glioblastoma

Clinical trials have tested methods enhancing the delivery of hydrophilic, high molecular weight compounds to brain tumors. These methods include convection-enhanced delivery, blood–brain barrier opening, chemotherapeutic modifications and conjugations that improve the transport of the active antitumor moiety, and osmotic or receptor-mediated opening of the blood–brain barrier [64–68]. Still, the new agents remain less effective than systemic chemotherapy using the hydrophobic agent temozolomide (Table 2).
Table 2. Comparison of methods to deliver therapeutic agents to glioblastoma.

| Drug delivery into brain tissue or lesion | Convection-Enhanced Delivery | BBB Opening | Systemic Chemotherapy |
|------------------------------------------|-----------------------------|-------------|-----------------------|
| **Drug delivery into brain tissue**      | During tissue infusion       | During the opening of the BBB | Limited by the intact BBB |
| **MW of therapeutic agent**              | Large or small              | Large or small | Small |
| **Brain–Blood Concentration**            | >100 × systemic concentration | ≤1 × systemic concentration | <1 × systemic concentration |
| **Hydrophilic compounds**                | Enters CNS                  | Enters CNS | Enters CNS |
| **Hydrophobic compounds**                | Enters CNS                  | The volume of distribution rests in the arterial distributions injected with mannitol | Entire CNS |
| **Distribution of Compound within CNS**  | Volume spreads radially from the infusion site | | |
| **The volume of the brain that can be treated** | Large (4–8 cm³) | Large (4–8 cm³) | Large (entire brain) |

Intratumoral drug delivery allows the use of drugs that would not be able to penetrate the blood–brain barrier due to their hydrophilic nature or high molecular weight. Convection-enhanced delivery can spread the therapeutic agent more widely throughout the tumor and brain than other methods of intratumoral drug delivery such as intracerebral bolus injection and slow-release polymers. Several modifications of convection-enhanced delivery catheters have been developed recently including a multi-port catheter capable of infusing several reagents simultaneously. A small phase 1 trial using this system demonstrated adequate tumor penetration, minimal back-flow, and a reasonable safety profile [69]. However, intratumoral drug delivery has had limited antitumor effects, either because the agents used were insufficiently tumoricidal or could not be delivered to the entire tumor volume (Table 3).

Table 3. Comparison of intracerebral drug delivery techniques.

| Speed of drug delivery into brain tissue or lesion | Convection-Enhanced Delivery | Bolus Intraleisional Therapy | Slow-Release Polymer |
|---------------------------------------------------|-----------------------------|-----------------------------|----------------------|
| **Speed of drug delivery**                        | Hours to days               | Seconds                     | Days to weeks        |
| **Means of the spread of drug**                   | Drug moves by bulk flow through the interstitial space | Drug moves by diffusion along concentration gradients | Drug moves by diffusion along concentration gradients |
| **Spread by MW**                                  | Small = Large MW            | Small > Large MW            | Small > Large MW     |
| **Variability in drug concentration**              | Homogeneous drug levels (1–100% of infused) within a brain volume | High concentration at infusion point with a steep fall-off in concentration throughout the surrounding brain | High concentration around polymer with a steep fall-off in concentration throughout the surrounding brain |
| **Depth of penetration of drug**                  | 15–20 mm                    | 1–4 mm                      | 1–4 mm               |
| **The volume of the brain that can be treated**   | Large (4–8 cm³)             | Small (mm³)                 | Small (mm³)          |

2.4.4. A Better Understanding of Tumor Components, Therapeutic Susceptibilities, and Mechanisms of Therapeutic Benefit May Lead to Improved Therapeutic Strategies for Glioblastoma

Small (1 cm³) and medium (50 cm³) glioblastomas follow radial linear, exponential, and Gompertzian growth curves, whereas tumor growth decelerates in large (125 cm³) glioblastomas, following a Gompertzian curve. In a recent study, 85% of glioblastomas with central non-contrast-enhancing areas were significantly larger (23.7 cm³) than the 15% of tumors (1.2 cm³) without central non-enhancing areas. Surprisingly, the non-contrast-enhancing component of the glioblastoma tumor grows at a faster rate than the contrast-enhancing tumor [70].

Cancer is a cellular disease whose cure requires the lethal treatment of every tumor cell. Substantially prolonged survival in glioblastoma depends on preventing tumor recurrence by eradicating tumor cells in the primary tumor mass and the surrounding and distant
brain regions. Conventional surgery and chemoradiation of glioblastoma effectively slow the growth of the tumor by eradicating the fastest dividing tumor cells that create the central mass of the tumor. Chemoradiation targets the fastest dividing cells most amenable to DNA damage, which cannot be repaired between rapid cell divisions. These therapies leave slower-dividing tumor clones to maintain glioblastoma growth. If this theory is correct, the present glioblastoma treatment essentially lengthens survival by eradicating the most rapidly dividing tumor clones. Life expectancy increases after the first wave of therapy because the glioblastoma growth rate falls when slower-dividing tumor clones drive it. If a tumor cure is presently unattainable and radio- and chemotherapy extend life by eliminating the fastest-growing tumor cell clones, therapies that slow the tumor cell cycle through non-DNA toxic treatments may be logical choices for treating recurrent glioblastoma. Future therapies may slow tumor growth by changing the tumor environment, providing time and a more conducive milieu for treatments such as immunotherapy to eradicate glioblastoma.

3. Conclusions

The improvement in glioblastoma prognosis and the development of effective therapies have not kept up with the tremendous advances in understanding the genetics, biology, and pathology of glioblastoma. Surgical treatment advances are limited because surgical resection cannot breach eloquent functional cortex and white matter tracts, preventing curative resections. Potentially curative radiotherapy doses are unsafe, causing radionecrosis of critical brain structures involved in the brain’s cognitive and other essential functions. Chemotherapy is often initially partially effective, but glioblastoma becomes progressively resistant to it. As a result, new and better treatments are sorely needed. Ongoing research into the mechanisms of the proliferation, invasion, and immune evasion of glioblastoma will identify new targets for glioblastoma therapy. Proven treatments, unique surgical tools, and novel molecularly-guided treatments provide a foundation for neurosurgeons to build more effective strategies for improving the care and extending the survival of patients with glioblastoma (Figure 1).

Figure 1. Schematic demonstrating new hybrid approaches for glioblastoma therapy.
Author Contributions: Conceptualization, A.H.S. and J.D.H.; methodology, A.H.S. and J.D.H.; resources, J.D.H.; writing—original draft preparation, J.D.H.; writing—review and editing, A.H.S. and J.D.H.; supervision, J.D.H.; project administration, A.H.S. and J.D.H.; funding acquisition, J.D.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Intramural Research Program of the National Institute of Neurological Diseases and Stroke at the National Institutes of Health.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Duffau, H. A new philosophy in surgery for diffuse low-grade glioma (DLGG): Oncological and functional outcomes. Neurolchirurgie 2013, 59, 2–8. [CrossRef] [PubMed]
2. Duffau, H. Resecting diffuse low-grade gliomas to the boundaries of brain functions: A new concept in surgical neuro-oncology. J. Neurosurg. Sci. 2015, 59, 361–371. [PubMed]
3. Kahn, E.; Lane, M.; Sagher, O. Elloquent: History of a word’s adoption into the neurosurgical lexicon. J. Neurosurg. 2017, 127, 1461–1466. [CrossRef] [PubMed]
4. Jelsma, R.; Bucy, P.C. Glioblastoma multiforme: Its treatment and some factors effecting survival. Arch. Neurol. 1969, 20, 161–171. [CrossRef] [PubMed]
5. Walker, M.D.; Strike, T.A.; Sheline, G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5, 1725–1731. [CrossRef]
6. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [CrossRef]
7. Cabrera, A.R.; Kirkpatrick, J.P.; Fiveash, J.B.; Shih, H.A.; Koay, E.J.; Lutz, S.; Petit, J.; Chao, S.T.; Brown, P.D.; Vogelbaum, M.; et al. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract. Radiat. Oncol. 2016, 6, 217–225. [CrossRef]
8. Sanai, N.; Mirzadeh, Z.; Berger, M.S. Functional outcome after language mapping for glioma resection. N. Engl. J. Med. 2008, 358, 18–27. [CrossRef] [PubMed]
9. Lacroix, M.; Abi-Said, D.; Fourney, D.R.; Gokaslan, Z.L.; Shi, W.; DeMonte, F.; Lang, F.F.; McCutcheon, I.E.; Hassenbusch, S.J.; Holland, E.; et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95, 190–198. [CrossRef]
10. Li, Y.M.; Suki, D.; Hess, K.; Sawaya, R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? J. Neurosurg. 2016, 124, 977–988. [CrossRef]
11. Roh, T.H.; Kang, S.G.; Moon, J.H.; Sung, K.S.; Park, H.H.; Kim, S.H.; Kim, E.H.; Hong, C.K.; Suh, C.O.; Chang, J.H. Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: A retrospective study. J. Neurosurg. 2019, 132, 895–901. [CrossRef] [PubMed]
12. Shah, A.H.; Mahavadi, A.; Di, L.; Sanjuro, A.; Eichberg, D.G.; Borowy, V.; Figueroa, J.; Luther, E.; de la Fuente, M.I.; Semonche, A.; et al. Survival benefit of lobectomy for glioblastoma: Moving towards radical supramaximal resection. J. Neurooncol. 2020, 148, 501–508. [CrossRef] [PubMed]
13. Haglund, M.M.; Berger, M.S.; Shamseldin, M.; Lettich, E.; Ojemann, G.A. Cortical localization of temporal lobe language sites in patients with gliomas. Neurosurgery 1994, 35, 567–576. [CrossRef] [PubMed]
14. Duffau, H. The reliability of asleep-awake-asleep protocol for intraoperative functional mapping and cognitive monitoring in glioma surgery. Acta Neurochir. 2013, 155, 1803–1804. [CrossRef] [PubMed]
15. Brown, T.; Shah, A.H.; Bregy, A.; Shah, N.H.; Thambuswamy, M.; Barbarie, E.; Fuhrman, T.; Komotar, R.J. Awake craniotomy for brain tumor resection: The rule rather than the exception? J. Neurosurg. Anesthesiol. 2013, 25, 240–247. [CrossRef] [PubMed]
16. Hansen, E.; Seemann, M.; Zech, N.; Doenitz, C.; Luerding, R.; Brawanski, A. Awake craniotomies without any sedation: The awake-awake-awake technique. Acta Neurochir. 2013, 155, 1417–1424. [CrossRef]
17. Kelly, P.J. Technology in the resection of gliomas and the definition of madness. J. Neurosurg. 2004, 101, 284–286. [CrossRef]
18. Senft, C.; Bink, A.; Franz, K.; Vatter, H.; Gasser, T.; Seifert, V. Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial. Lancet Oncol. 2011, 12, 997–1003. [CrossRef]
19. Weingarten, D.M.; Asthagiri, A.R.; Butman, J.A.; Sato, S.; Wiggs, E.A.; Damaska, B.; Heiss, J.D. Cortical mapping and frameless stereotactic navigation in the high-field intraoperative magnetic resonance imaging suite. J. Neurosurg. 2009, 111, 1185–1190. [CrossRef]
20. Deora, H.; Ferini, G.; Garg, K.; Narayanan, M.D.K.; Umana, G.E. Evaluating the Impact of Intraoperative MRI in Neuro-Onco
logy by Scientometric Analysis. Life 2022, 12, 175. [CrossRef]
21. Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zenolla, F.; Reulen, H.J. Fluorescence-guided surgery with 5-aminolevulinic
acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7, 392–401. [CrossRef]
22. Stummer, W.; Tonn, J.C.; Mehdorn, H.M.; Nestler, U.; Franz, K.; Goetz, C.; Bink, A.; Pichlmeier, U. Counterbalancing risks and

gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic
acid glioma resection study. J. Neurosurg. 2011, 114, 613–623. [CrossRef] [PubMed]
23. Hadijianipanayis, C.G.; Stummer, W. 5-ALA and FDA approval for glioma surgery. J. Neurooncol. 2019, 141, 479–486. [CrossRef] [PubMed]
24. Bowden, S.G.; Neira, J.A.; Gill, B.J.A.; Ung, T.H.; Engleander, Z.K.; Zanazzi, G.; Chang, P.D.; Samanamud, J.; Grinband, J.;
Sheth, S.A.; et al. Sodium Fluorescein Facilitates Guided Sampling of Diagnostic Tumor Tissue in Nonenhancing Gliomas. Neurosurgery 2018, 82, 719–727. [CrossRef]
25. Schupper, A.J.; Rao, M.; Mohammadi, N.; Baron, R.; Lee, J.Y.K.; Acerbi, F.; Hadijianipanayis, C.G. Fluorescence-Guided Surgery: A
Review on Timing and Use in Brain Tumor Surgery. Front. Neurol. 2021, 12, 682151. [CrossRef]
26. Eyupoglu, I.Y.; Hore, N.; Fan, Z.; Buslei, R.; Merkel, A.; Buchfelder, M.; Savaskan, N.E. Intraoperative vascular DIVA surgery
reveals angiographic hotspots in tumor zones of malignant gliomas. Sci. Rep. 2015, 5, 7958. [CrossRef]
27. Ji, M.; Orringer, D.A.; Freudiger, C.W.; Ramkissoon, S.; Liu, X.; Lau, D.; Golby, A.J.; Norton, I.; Hayashi, M.; Agar, N.Y.; et al. Rapid,
label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci. Transl. Med. 2013, 5, 201ra119. [CrossRef]
28. Hollon, T.C.; Pandian, B.; Adapa, A.R.; Urias, E.; Save, A.V.; Khalsa, S.S.S.; Eichberg, D.G.; D’Amico, R.S.; Farooq, Z.U.;
Lewis, S.; et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nat. Med. 2020, 26, 52–58. [CrossRef]
29. Eichberg, D.G.; Shah, A.H.; Di, L.; Semonche, A.M.; Jimsheleishvili, G.; Luther, E.M.; Sarkiss, C.A.; Levi, A.D.; Gul
tekin, S.H.; Komotar, R.J.; et al. Stimulated Raman histology for rapid and accurate intraoperative diagnosis of CNS tumors: Prospective
blinded study. J. Neurosurg. 2019, 134, 137–143. [CrossRef]
30. Di, L.; Eichberg, D.G.; Huang, K.; Shah, A.H.; Jamshidi, A.M.; Luther, E.M.; Lu, V.M.; Komotar, R.J.; Ivan, M.E.; Gul
tekin, S.H. Stimulated Raman Histology for Rapid Intraoperative Diagnosis of Gliomas. World Neurosurg. 2021, 150, e135–e143. [CrossRef]
31. Hollon, T.C.; Lewis, S.; Pandian, B.; Niknafs, Y.S.; Garrard, M.R.; Garton, H.; Maher, C.O.; McFadden, K.; Snuderl, M.;
Lieberman, A.P.; et al. Rapid Intraoperative Diagnosis of Pediatric Brain Tumors Using Stimulated Raman Histology. Cancer Res. 2018, 78, 278–289. [CrossRef] [PubMed]
32. Karabeber, H.; Huang, R.; Iacono, P.; Samii, J.M.; Pitter, K.; Holland, E.C.; Kircher, M.F. Guiding brain tumor resection using
surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. ACS Nano 2014, 8, 9755–9766. [CrossRef] [PubMed]
33. Daoust, F.; Nguyen, T.; Orsini, P.; Bismuth, J.; de Denus-Baillargeon, M.M.; Veilleux, I.; Wetter, A.; McKeown, P.; Dicaire, I.; Massabki, M.; et al. Handheld Macroscopic Raman Spectroscopy Imaging Instrument for Machine-Learning-Based Molecular Tissue Margins Characterization. J. Biomed. Opt. 2021, 26, 022911. [CrossRef]
34. Harrison, R.A.; Ou, A.; Naqvi, S.; Naqvi, S.M.; Weathers, S.S.; O’Brien, B.J.; de Groot, J.F.; Bruera, E. Aggressiveness of care at end of
life in patients with high-grade glioma. Cancer Med. 2021, 10, 8387–8394. [CrossRef] [PubMed]
35. Sagberg, L.M.; Solheim, O.; Jakola, A.S. Quality of survival the 1st year with glioblastoma: A longitudinal study of patient-reported
quality of life. J. Neurosurg. 2016, 124, 989–997. [CrossRef] [PubMed]
36. Choudry, U.K.; Shaikh, H.I.; Nisar, A.; Khan, S.A.; Shamim, M.S. Role of extent of resection on quality of life in patients with
newly diagnosed GBM. J. Pak. Med. Assoc. 2018, 68, 142–144. [PubMed]
37. McGirt, M.J.; Mukherjee, D.; Chaichana, K.L.; Than, K.D.; Weingart, J.D.; Quinones-Hinojosa, A. Association of surgically acquired
motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 2009, 65, 463–469. [CrossRef]
38. Tanglay, O.; Young, I.M.; Dadario, N.B.; Taylor, H.M.; Nicholas, P.J.; Doyen, S.; Sughrue, M.E. Eigenvector PageRank difference as a measure to reveal topological characteristics of the brain connectome for neurosurgery. J. Neurooncol. 2022, 157, 49–61. [CrossRef]
39. Dadario, N.B.; Sughrue, M.E. Should Neurosurgeons Try to Preserve Non-Traditional Brain Networks? A Systematic Review of the Neuroscientific Evidence. J. Pers. Med. 2022, 12, 587. [CrossRef]
40. Doyen, S.; Nicholas, P.; Pooologandran, A.; Crawford, L.; Young, I.M.; Romero-Garcia, R.; Sughrue, M.E. Connectivity-based
parcellation of normal and anatomically distorted human cerebral cortex. Hum. Brain Mapp. 2022, 43, 1358–1369. [CrossRef]
41. Saviola, F.; Zigiotto, L.; Novello, L.; Zaca, D.; Annicchiarico, L.; Corsini, F.; Rozzani, U.; Papagno, C.; Jovicich, J.; Sarubbo, S. The role of the default mode network in longitudinal functional brain reorganization of brain gliomas. Brain Struct. Funct. 2022, ahead of print. [CrossRef] [PubMed]
42. Shah, A.H.; Burks, J.D.; Buttrick, S.S.; Debs, L.; Ivan, M.E.; Komotar, R.J. Laser Interstitial Thermal Therapy as a Primary Treatment for Deep Inaccessible Gliomas. Neurosurgery 2019, 84, 768–777. [CrossRef] [PubMed]
43. Lee, I.; Kalkanis, S.; Hadjipanayis, C.G. Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas. *Neurosurgery* 2016, 79 (Suppl. 1), S24–S34. [CrossRef] [PubMed]

44. Di, L.; Wang, C.P.; Shah, A.H.; Eichberg, D.G.; Semonche, A.M.; Sanjurjo, A.D.; Luther, E.M.; Jermakowicz, W.J.; Komotar, R.J.; Ivan, M.E. A Cohort Study on Prognostic Factors for Laser Interstitial Thermal Therapy Success in Newly Diagnosed Glioblastoma. *Neurosurgery* 2021, 89, 496–503. [CrossRef] [PubMed]

45. Shah, A.H.; Semonche, A.; Eichberg, D.G.; Borow, V.; Luther, E.; Sarkiss, C.A.; Morell, A.; Mahavadi, A.K.; Ivan, M.E.; Komotar, R.J. The Role of Laser Interstitial Thermal Therapy in Surgical Neuro-Oncology: Series of 100 Consecutive Patients. *Neurosurgery* 2020, 87, 266–275. [CrossRef]

46. Ivan, M.E.; Mohammad, A.M.; De Deugd, N.; Reyes, J.; Rodriguez, G.; Shah, A.; Barnett, G.H.; Komotar, R.J. Laser Ablation of Newly Diagnosed Malignant Gliomas: A Meta-Analysis. *Neurosurgery* 2016, 79 (Suppl. 1), S17–S23. [CrossRef]

47. Salehi, A.; Patiur, M.R.; Patel, B.; Cain, M.D.; Mahlokozera, T.; Yang, A.B.; Lin, T.H.; Leuthardt, E.C.; Yano, H.; Song, S.K.; et al. Therapeutic enhancement of blood-brain and blood-tumor barriers permeability by laser interstitial thermal therapy. *Neuroradiol. Adv.* 2020, 2, vdaa071. [CrossRef] [PubMed]

48. Leuthardt, E.C.; Duan, C.; Kim, M.J.; Campian, J.L.; Kim, A.H.; Miller-Thomas, M.M.; Shimony, J.S.; Tran, D.D. Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier. *PLoS ONE* 2016, 11, e0146613. [CrossRef]

49. Stupp, R.; Taillibert, S.; Kushner, A.A.; Kesari, S.; Steinberg, D.M.; Toms, S.A.; Taylor, L.P.; Lieberman, F.; Silvani, A.; Fink, K.L.; et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. *JAMA* 2015, 314, 2535–2543. [CrossRef]

50. Reardon, D.A.; Brandes, A.A.; Omuro, A.; Mulholland, P.; Lim, M.; Wick, A.; Baehring, J.; Ahluwalia, M.; Roth, P.; Bähr, O.; et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2020, 6, 1003–1010. [CrossRef]

51. Johnson, L.A.; Scholler, J.; Ohkuri, T.; Kosaka, A.; Patel, P.R.; McGettigan, S.E.; Loew, A.; et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. *Sci. Transl. Med.* 2015, 7, 275ra222. [CrossRef] [PubMed]

52. O’Rourke, D.M.; Nasrallah, M.P.; Desai, A.; Melenhorst, J.J.; Masuyer, E.; Martinez-Lage, M.; Brem, S.; Maloney, E.; Shen, A.; et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci. Transl. Med.* 2017, 9, eaao984. [CrossRef] [PubMed]

53. Lin, Y.J.; Mashouf, L.A.; Lim, M. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. *Front. Immunol.* 2022, 13, 817296. [CrossRef] [PubMed]

54. Andrews, D.W.; Judy, K.D.; Scott, C.B.; Garcia, S.; Harshyne, L.A.; Kenyon, L.; Talekar, K.; Loew, A.; et al. Phase Ib Clinical Trial of IVG-001 for Patients with Newly Diagnosed Glioblastoma. *Clin. Cancer Res.* 2021, 27, 1912–1922. [CrossRef]

55. Lang, F.F.; Bruner, J.M.; Fuller, G.N.; Aldape, K.; Prados, M.D.; Chang, S.; Berger, M.S.; McDermott, M.W.; Kunwar, S.M.; Junck, L.R.; et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. *J. Clin. Oncol.* 2003, 21, 2508–2518. [CrossRef]

56. Cloughesy, T.F.; Landolfi, J.; Hogan, D.J.; Bloomfield, S.; Carter, B.; Chen, C.C.; Elder, J.B.; Kalkanis, S.N.; Kesari, S.; Lai, A.; et al. Phase I trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. *Sci. Transl. Med.* 2016, 8, 341ra375. [CrossRef]

57. Wheeler, L.A.; Manzanera, A.G.; Bell, S.D.; Cavaliere, R.; McGregor, J.M.; Grecula, J.C.; Newton, H.B.; Lo, S.S.; Badie, B.; Portnow, J.; et al. Phase II multicenter study of gene-mediated cytotoxic immunomodulation as adjuvant to surgical resection for newly diagnosed malignant glioma. *Neuro Oncol.* 2016, 18, 1137–1145. [CrossRef]

58. Cloughesy, T.F.; Petrecca, K.; Walbert, T.; Butowski, N.; Salacz, M.; Perry, J.; Damek, D.; Bettegowda, C.; Zhu, J.J.; et al. Effect of Vocimagene Amiretrorepvec in Combination With Fluocytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. *JAMA Oncol.* 2020, 6, 1939–1946. [CrossRef]

59. Friedman, G.K.; Johnston, J.M.; Bag, A.K.; Bernstock, J.D.; Li, R.; Aban, I.; Kachurak, K.; Nan, L.; Kang, K.D.; Totsch, S.; et al. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. *N. Engl. J. Med.* 2021, 384, 1613–1622. [CrossRef]

60. Fulci, G.; Breymann, L.; Gianni, D.; Kurozomi, K.; Rhee, S.S.; Yu, J.; Kaur, B.; Louis, D.N.; Weissleder, R.; Caligiuri, M.A.; et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. *Proc. Natl. Acad. Sci. USA* 2006, 103, 12873–12878. [CrossRef] [PubMed]

61. Bernstock, J.D.; Hoffman, S.E.; Chen, J.A.; Gupta, S.; Kappel, A.D.; Smith, T.R.; Chiocca, E.A. The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies. *Viruses* 2021, 13, 1158. [CrossRef] [PubMed]

62. van Putten, E.H.P.; Kleijn, A.; van Beusechem, V.W.; Noske, D.; Lamers, C.H.J.; de Goede, A.L.; Idema, S.; Hoefnagel, D.; Kloeze-Man, J.J.; Fueno, J.; et al. Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies. *Clin. Cancer Res.* 2022, 28, 1572–1585. [CrossRef] [PubMed]

63. Laspidou, V.; Puigdelloses, M.; Labiano, S.; Marron, L.; Garcia-Moure, M.; Salacain, M.; Gonzalez-Huarriz, M.; Martinez-Velez, N.; Ausejo-Mauleon, I.; de la Nava, D.; et al. Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas. *JCI Insight.* 2022, 7, e154812. [CrossRef] [PubMed]
64. Jackson, S.; Weingart, J.; Nduom, E.K.; Harfi, T.T.; George, R.T.; McAreevey, D.; Ye, X.; Anders, N.M.; Peer, C.; Figg, W.D.; et al. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. *Fluids Barriers CNS* 2018, 15, 2. [CrossRef] [PubMed]

65. Kuo, Y.C.; Lee, C.L. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. *Colloids Surf. B Biointerfaces* 2012, 90, 75–82. [CrossRef] [PubMed]

66. Neuwelt, E.A.; Howieson, J.; Frenkel, E.P.; Specht, H.D.; Weigel, R.; Buchan, C.G.; Hill, S.A. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. *Neurosurgery* 1986, 19, 573–582. [CrossRef] [PubMed]

67. Riley, M.G.; Kim, N.N.; Watson, V.E.; Gobin, Y.P.; LeBel, C.P.; Black, K.L.; Bartus, R.T. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: A toxicologic evaluation in swine. *J. Neurooncol.* 1998, 36, 167–178. [CrossRef]

68. Vezina, A.; Manglani, M.; Morris, D.; Foster, B.; McCord, M.; Song, H.; Zhang, M.; Davis, D.; Zhang, W.; Bills, J.; et al. Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model. *Mol. Cancer Res.* 2021, 19, 2081–2095. [CrossRef]

69. Vogelbaum, M.A.; Brewer, C.; Barnett, G.H.; Mohammadi, A.M.; Peereboom, D.M.; Ahluwalia, M.S.; Gao, S. First-in-human evaluation of the Cleveland MultiPort Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: Results of pilot trial 1. *J. Neurosurg.* 2018, 1–10, ahead of print. [CrossRef]

70. Stensjøen, A.L.; Solheim, O.; Kvistad, K.A.; Håberg, A.K.; Salvesen, Ø.; Berntsen, E.M. Growth dynamics of untreated glioblastomas in vivo. *Neuro. Oncol.* 2015, 17, 1402–1411. [CrossRef]